Adcock Ingram’s Urizone Wins Trademark Battle
Adcock Ingram's Urizone receives legal protection as the court halts Cipla's Furizome, citing trademark infringement.
Aspen Pharmacare Manufacturing Dispute Shrouded in Mystery
Explore the Aspen Pharmacare manufacturing dispute and its potential impact on core earnings for the 2025 financial year.
NHI Advertising Campaign Proceeds Despite HIV Funding Shortfall
Health Minister Aaron Motsoaledi discusses the NHI advertising campaign designed to address misinformation and support health efforts.
Lilly’s Orforglipron Shows Significant Weight Loss in Phase 3 Trial
Orforglipron can offer a new oral option for managing weight loss and blood sugar in type 2 diabetes treatment.
Clicks Interim Results Driven by Loyalty and Digital Sales
Read about the Clicks interim results that reveal a 13.2% rise in headline earnings per share and significant market achievements.
Trump Drug Price Executive Order Targets Medicare Negotiations
Get insights on the Trump drug price executive order and how it may reshape timelines for drug price negotiations.